Medicine, however, Schutte and his colleagues in Texas have reported that they had identified a dominantly inherited syndrome of mitral valve prolapse in people with distinctive anthropometric characteristics.9 Their patients had narrow anteroposterior chest diameters and longer armspans than controls. Unfortunately, the altered habitus was present only in women, and the value of measuring bodily proportions as a diagnostic discriminant in sporadic patients with mitral valve prolapse is therefore limited.
From the genetic standpoint, Schutte et a19 claimed that their findings in first degree relatives in three families were indicative of autosomal dominant inheritance of the syndrome. The lack of pedigree data for formal analysis, however, and the fact that the habitus was not present in men make it difficult to accept their proposals unreservedly. Moreover, in two further instances the results of family studies were negative. Notwithstanding these reservations, however, the diagnostic appraisal of possible heart abnormalities of potentially affected close relatives of individuals with the syndrome seems to be warranted.
The question inevitably arises whether these patients have the Marfan syndrome. The full-blown syndrome, with disproportion of the length of the limbs, arachnodactyly, and dislocated ocular lenses is unmistakable. Nevertheless, atypical or partial examples abound, and as there are no absolute diagnostic criteria diagnostic certainty is often impossible. Schutte et a19 were at pains, however, to exclude individuals with the stigmata of the Marfan syndrome from their series, so this red herring can probably be discounted.
In view of the complexity of the collagen molecule, and on the basis of precedents for extreme degrees of heterogeneity in other conditions, there seem likely to be numerous undelineated disorders of connective tissue where mitral valve prolapse is a syndromic component. Indeed, Schutte et a19 may have already recognised one such entity. These disorders are, however, "soft syndromes," and in the absence of any biochemical marker firm delineation is well-nigh impossible.
As with many problems in medical genetics, resolution of this diagnostic dilemma may ultimately be achieved through recombinant DNA technology.
PETER BEIGHTON 
Immunotherapy reassessed
For 20 years now research workers have been looking into the immunotherapy of cancer but clinicians still do not know whether it is useful for their patients. The concept of a simple treatment that might "mop up" the last remaining cancer cell after initial treatment with surgery or radiotherapy is attractive. Medawar's work in the 1950s on tissue recognition and the rejection of foreign cells and proteins started a hunt for tumour-specific antigens.' A series of experiments2-4 in specially inbred strains of mice showed that tumour-specific transplantation antigens did indeed exist in tumours induced in these mice by chemicals. The combination of this evidence with studies showing that immunotherapy (usually with BCG5 6) worked in experimental tumours in animals raised great hopes for the immunotherapy of human cancer. Sadly, these hopes were largely disappointed as overenthusiastic clinicians began to use "immunotherapy" in a chaotic fashion destined to give results that could not be assessed. Indeed, even while these studies were starting warning voices were suggesting that data from research on animals could not be used to develop a treatment for human tumours.
Naturally occurring cancers differ from the experimental models in several ways. They are weakly antigenic and are less susceptible to immunological attack. In addition, experimental immunotherapy in animals works only when small numbers of tumour cells (< 10 x 106) are injected. As Old and Boyse7 wrote: "Despite the evident antigenicity of a variety of [tumours in] experimental animals, it is a fact that no immunological measure is known that will cause the rejection of an established malignant tumour." Experimental tumours, in contrast to most human cancers, grow rapidly with short doubling times and are biologically different from spontaneous tumours. The evidence also suggests that host resistance is more complex than was at first thought. 8 
